125 related articles for article (PubMed ID: 17889580)
1. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.
Dal Negro RW; Visconti M; Micheletto C; Tognella S
Pulm Pharmacol Ther; 2008; 21(2):304-8. PubMed ID: 17889580
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
3. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
Dal Negro RW; Visconti M
Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
[TBL] [Abstract][Full Text] [Related]
4. Erdosteine affects eicosanoid production in COPD.
Dal Negro RW; Visconti M; Tognella S; Micheletto C
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):41-5. PubMed ID: 21176724
[TBL] [Abstract][Full Text] [Related]
5. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.
Dal Negro R; Visconti M; Trevisan F; Bertacco S; Micheletto C; Tognella S
Ther Adv Respir Dis; 2008 Oct; 2(5):271-7. PubMed ID: 19124377
[TBL] [Abstract][Full Text] [Related]
6. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
7. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
8. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
9. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
10. Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures.
Vagliasindi M; Fregnan GB
Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):238-41. PubMed ID: 2786856
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease.
Knobloch J; Sibbing B; Jungck D; Lin Y; Urban K; Stoelben E; Strauch J; Koch A
J Pharmacol Exp Ther; 2010 Dec; 335(3):788-98. PubMed ID: 20801891
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).
Marchioni CF; Polu JM; Taytard A; Hanard T; Noseda G; Mancini C
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):612-8. PubMed ID: 8688986
[TBL] [Abstract][Full Text] [Related]
14. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
[TBL] [Abstract][Full Text] [Related]
15. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study.
de Matos Cavalcante AG; de Bruin PF; de Bruin VM; Nunes DM; Pereira ED; Cavalcante MM; Andrade GM
J Pineal Res; 2012 Oct; 53(3):238-44. PubMed ID: 22507631
[TBL] [Abstract][Full Text] [Related]
16. Airway inflammatory markers in chronic obstructive pulmonary disease patients and healthy smokers.
Hacievliyagil SS; Mutlu LC; Temel İ
Niger J Clin Pract; 2013; 16(1):76-81. PubMed ID: 23377476
[TBL] [Abstract][Full Text] [Related]
17. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
18. Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease.
Votto JJ; Bowen JB; Barton RW; Thrall RS
J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):329-34. PubMed ID: 18800883
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
20. An overview of erdosteine antioxidant activity in experimental research.
Moretti M; Marchioni CF
Pharmacol Res; 2007 Apr; 55(4):249-54. PubMed ID: 17267240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
